Friday, August 6, 2010

Novartis's Facebook Share This Widget gets warning letter from FDA

Pin It Now!
The Pharma Marketing blog took a look at the FDA letter Novartis received because of the "Share This" widget on their webpage. Received on July 29, the letter issued them a warning for not properly warning of the risks associated with the drug.

According to the Pharma Marketing blog, the one of the FDA reasoning for issuing this letter was:
"Facebook Share is a way for users of Facebook to share articles, pages, video, or flash content of a site with other Facebook users. Over two billion pieces of content are shared each week through Facebook. With two clicks, visitors to a website can share any page of that website through Facebook by generating a link to the page, along with a thumbnail image and a brief description (i.e., 'shared content') that will appear on the users’ profiles and, depending on privacy settings, in the home page stream of all of the users’ friends. Each time a link is shared by one user, potentially hundreds of new people may see and/or click through on the link."

Upon receiving the letter, they did pull the "Share This" feature on their Facebook page. Read Pharma Marketing's full article about the FDA letter here.
Post a Comment